Gayatri BioOrga.

  • Market Cap: Micro Cap
  • Industry: Commodity Chemicals
  • ISIN: INE052E01015
  • NSEID:
  • BSEID: 524564
INR
7.64
-0.31 (-3.9%)
BSENSE

Aug 11, 03:30 PM

BSE+NSE Vol: 7.96 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

7.96 k (-26.91%) Volume

Shareholding (Jun 2026)

FII

0.01%

Held by 1 FIIs

DII

0.23%

Held by 0 DIIs

Promoter

21.59%

Why is Gayatri BioOrganics Ltd falling/rising?

10-Aug-2026

As of 10-Aug, Gayatri BioOrganics Ltd's stock price is at 7.95, reflecting a decline after four days of gains and underperforming its sector by 6.03%. Investor participation has decreased significantly, indicating reduced interest, while the stock remains below longer-term moving averages, suggesting a weaker trend.

As of 10-Aug, Gayatri BioOrganics Ltd's stock price is falling, currently at 7.95, which reflects a decrease of 0.05 or 0.62%. This decline follows a trend reversal after four consecutive days of gains. Additionally, the stock has underperformed its sector by 6.03% today. <BR><BR>Investor participation has also decreased, with delivery volume dropping by 29.98% compared to the 5-day average, indicating reduced interest from investors. While the stock is currently trading above its 5-day and 20-day moving averages, it remains below the longer-term moving averages of 50, 100, and 200 days, suggesting a weaker long-term trend. <BR><BR>Overall, these factors contribute to the stock's current downward movement.

View full answer

Are Gayatri BioOrganics Ltd latest results good or bad?

05-Aug-2026

Gayatri BioOrganics Ltd's latest results are concerning, showing a marginal revenue of ₹2.34 crores but a net loss of ₹0.10 crores and negative equity of ₹-4.56 per share, indicating significant financial distress and ongoing operational struggles.

The latest results for Gayatri BioOrganics Ltd indicate a challenging financial situation. While the company reported its first revenue in seven quarters, amounting to ₹2.34 crores in Q1 FY27, it still faced significant losses, with a net profit of ₹-0.10 crores. This reflects continued operational struggles despite the marginal revenue generation.<BR><BR>The company's operating profit was just ₹0.01 crores, which was completely offset by interest costs of ₹0.11 crores, highlighting its inability to cover even basic financial obligations. Additionally, Gayatri BioOrganics has a negative book value of ₹-4.56 per share and a market capitalization of only ₹58.85 crores, indicating severe financial distress and technical insolvency.<BR><BR>Overall, while there was a slight glimmer of activity with the emergence of revenue, the underlying financial health remains precarious, and the results can be characterized as bad given the ongoing losses and negative equity position.

View full answer

Should I buy, sell or hold Gayatri BioOrganics Ltd?

05-Aug-2026

When is the next results date for Gayatri BioOrganics Ltd?

31-Jul-2026

The next results date for Gayatri BioOrganics Ltd is August 4, 2026.

The next results date for Gayatri BioOrganics Ltd is scheduled for August 4, 2026.

View full answer

How big is Gayatri BioOrga.?

11-Jun-2026

As of 10th June, Gayatri BioOrganics Ltd has a market capitalization of 62.00 Cr, with reported Net Sales of 0.00 Cr and a Net Profit loss of 1.11 Cr in the latest four quarters. The balance sheet as of March 2025 shows Shareholder's Funds at a loss of 35.89 Cr and Total Assets valued at 1.66 Cr.

As of 10th June, Gayatri BioOrganics Ltd has a market capitalization of 62.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 0.00 Cr and a Net Profit loss of 1.11 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, showing Shareholder's Funds at a loss of 35.89 Cr and Total Assets valued at 1.66 Cr.

View full answer

Who are in the management team of Gayatri BioOrga.?

11-Jun-2026

The management team of Gayatri BioOrga includes T V Sandeep Kumar Reddy (Executive Chairman), Murali Vittala, P V Narayana Rao, Ch Ramachandra Seshaprasad (all Independent Directors), K. Sridhar Reddy (Whole-time Director), Meenakshi Ramchand Sachdeva (Director), and Aamir Tak (Company Secretary & Compliance Officer).

The management team of Gayatri BioOrga includes the following individuals:<BR><BR>1. T V Sandeep Kumar Reddy - Executive Chairman<BR>2. Murali Vittala - Independent Director<BR>3. P V Narayana Rao - Independent Director<BR>4. Ch Ramachandra Seshaprasad - Independent Director<BR>5. K. Sridhar Reddy - Whole-time Director<BR>6. Meenakshi Ramchand Sachdeva - Director<BR>7. Aamir Tak - Company Secretary & Compliance Officer<BR><BR>If you need more details about any specific member or their roles, feel free to ask!

View full answer

Who are the peers of the Gayatri BioOrga.?

11-Jun-2026

Peers of Gayatri BioOrga. include ARCL Organics, AG Ventures, Archit Organosys, Polychem, Sh. Hari Chem., Ritesh Intl., Shreyas Interm., Camex, and TCM. Ritesh Intl. has the highest 1-year return at 24.60%, while Gayatri BioOrga. has a 1-year return of 6.02%.

Peers: The peers of Gayatri BioOrga. are ARCL Organics, AG Ventures, Archit Organosys, Polychem, Sh. Hari Chem., Ritesh Intl., Shreyas Interm., Camex, and TCM.<BR><BR>Quality Snapshot: Excellent management risk is observed at ARCL Organics, while Average management risk is found at Polychem, Sh. Hari Chem., and Ritesh Intl., and the rest have Below Average management risk. Growth is rated as Good at Sh. Hari Chem., while Average growth is noted at Polychem, Ritesh Intl., and Archit Organosys, and the rest have Below Average growth. Capital Structure is Excellent at AG Ventures, Good at ARCL Organics and Polychem, Average at Archit Organosys and Camex, and the rest have Below Average or do not qualify.<BR><BR>Return Snapshot: Ritesh Intl. has the highest 1-year return at 24.60%, while AG Ventures has the lowest at -59.81%. Gayatri BioOrga.'s own 1-year return is 6.02%, which is higher than AG Ventures but lower than Ritesh Intl. Additionally, the six-month returns are negative for ARCL Organics, AG Ventures, Polychem, Sh. Hari Chem., Shreyas Interm., TCM, and Gayatri BioOrga.

View full answer

What does Gayatri BioOrga. do?

10-Jun-2026

Gayatri BioOrganics Ltd is a micro-cap company in the commodity chemicals industry, previously known as Starchem Industries, with no net profit reported for March 2026 and a market cap of INR 62 Cr. The company has a negative debt-equity ratio and a low return on equity of 2.73%.

Overview:<BR>Gayatri BioOrganics Ltd operates in the commodity chemicals industry and is classified as a micro-cap company.<BR><BR>History:<BR>The company was initially incorporated as 'Starchem Industries Limited' in 1991. It underwent several name changes, becoming Gayatri Starchem Limited in 1997 and finally Gayatri BioOrganics Limited in 2008. The latest quarterly results reported are for March 2026, showing no net profit.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2026)<BR>Market-cap value: INR 62 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A<BR>Industry P/E: 42<BR>Dividend Yield: 0.00%<BR>Debt-Equity: -1.02<BR>Return on Equity: 2.73%<BR>Price to Book: -1.75<BR><BR>Contact Details:<BR>Address: 6-3-1090 B-Block 3rd Floor, TSRTowers, Rajbhavan Rd, Somajiguda, Hyderabad, Telangana: 500082<BR>Tel: 91-40-66100111<BR>Email: info@gayatribioorganics.com<BR>Website: http://www.gayatribioorganics.com

View full answer

How has been the historical performance of Gayatri BioOrga.?

14-Nov-2025

Gayatri BioOrga has faced significant financial challenges, reporting minimal revenue and consistent losses, with net sales dropping to zero in 2024 and 2025, and negative reserves of -114.68 Cr by March 2025. The company has not generated any cash flow from operations since March 2020.

Answer:<BR>The historical performance of Gayatri BioOrga shows a challenging trend with minimal revenue generation and consistent losses over the years.<BR><BR>Breakdown:<BR>Gayatri BioOrga reported net sales of 1.67 Cr in March 2023, but this figure dropped to 0.00 Cr in both March 2024 and March 2025, indicating a complete halt in revenue generation. The total operating income mirrored this trend, remaining at 0.00 Cr for the last two years after a peak in March 2023. The company's expenditures, excluding depreciation, were 2.44 Cr in March 2023, decreasing to 0.45 Cr by March 2025, yet the operating profit continued to be negative, with losses of -0.45 Cr in March 2025 compared to -0.77 Cr in March 2023. The profit before tax also remained negative, with a loss of -0.73 Cr in March 2025. The company's reserves have been in a negative state, reaching -114.68 Cr in March 2025, while shareholder's funds also reflected a negative balance of -35.89 Cr. Cash flow from operating activities has been non-existent since March 2020, with no cash inflow or outflow reported in the last three years. Overall, Gayatri BioOrga's financial performance indicates significant operational challenges and a lack of profitability.

View full answer

Is Gayatri BioOrga. overvalued or undervalued?

09-Jun-2025

As of April 25, 2023, Gayatri BioOrga is classified as risky and overvalued, with negative key ratios indicating financial struggles, despite a 34.16% return over the past year, outperforming the Sensex's 7.57%.

As of 25 April 2023, the valuation grade for Gayatri BioOrga. has moved from does not qualify to risky. The company is currently assessed as overvalued. Key ratios include a PE ratio of -58.43, an EV to EBIT of -95.74, and a ROCE of -38.46%. <BR><BR>In comparison to peers, Solar Industries is classified as very expensive with a PE ratio of 123.77, while Godrej Industries is attractive with a PE ratio of 46.63. The significant negative ratios for Gayatri BioOrga. suggest that the company is struggling financially, which is reflected in its poor performance relative to the Sensex, although it has outperformed the index over the past year with a return of 34.16% compared to the Sensex's 7.57%.

View full answer

What is the technical trend for Gayatri BioOrga.?

09-Jun-2025

As of May 14, 2025, Gayatri BioOrga's technical trend is bullish, supported by strong daily and weekly indicators, despite mild bullishness in the monthly MACD and KST.

As of 14 May 2025, the technical trend for Gayatri BioOrga has changed from mildly bullish to bullish. The weekly MACD is bullish, supporting the positive trend, while the daily moving averages also indicate a bullish stance. The weekly KST is bullish, further reinforcing the upward momentum. Although the monthly MACD and KST are only mildly bullish, the overall strength of the trend is supported by the daily indicators. The Bollinger Bands are mildly bullish on both weekly and monthly time frames, suggesting a potential for continued upward movement. The Dow Theory shows a mildly bullish trend on the weekly chart, but no trend on the monthly. Overall, the current technical stance is bullish with strong indicators from the daily and weekly time frames.

View full answer

Who are the top shareholders of the Gayatri BioOrga.?

06-Jun-2025

The top shareholders of Gayatri BioOrga include promoter Sandeep Kumar Reddy Tikkavarapu with 21.59% and public shareholder Fursa Mauritius Spv 1 with 23.48%. Individual investors hold 53.01% of shares, while mutual funds and foreign institutional investors hold minor stakes.

The top shareholders of Gayatri BioOrga include Sandeep Kumar Reddy Tikkavarapu, who is the promoter with the highest holding at 21.59%. Additionally, the highest public shareholder is Fursa Mauritius Spv 1, holding 23.48%. Individual investors collectively hold 53.01% of the shares. The company also has some mutual fund representation, with three schemes holding 0.65%, and one foreign institutional investor holding 0.01%. There are no pledged promoter holdings reported.

View full answer

Has Gayatri BioOrga. declared dividend?

06-Jun-2025

No Dividend History Available

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

  • Poor long term growth as Net Sales has grown by an annual rate of % and Operating profit at 0% over the last 5 years
  • The company has a negative book value of Rs 37.00 crore
2

Flat results in Jun 26

3

Risky - Negative EBITDA

4

Below par performance in long term as well as near term

stock-summaryMojo Parameters

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

stock-summary
Industry

Commodity Chemicals

stock-summary
Market cap

INR 61 Cr (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

44

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.02

stock-summary
Return on Equity

2.73%

stock-summary
Price to Book

-1.60

Revenue and Profits:
Net Sales:
2 Cr
(Quarterly Results - Jun 2026)
Net Profit:
0 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-55.58%
0%
-55.58%
6 Months
-44.64%
0%
-44.64%
1 Year
-39.51%
0%
-39.51%
2 Years
35.22%
0%
35.22%
3 Years
-31.66%
0%
-31.66%
4 Years
-41.95%
0%
-41.95%
5 Years
-42.38%
0%
-42.38%

Gayatri BioOrga. for the last several years.

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions

News

Announcements stock-summary

Resignation Of Mr. Venkata Sandeep Kumar Reddy Tikkavarapu As Chairman And Non-Executive Director Of The Company.

05-Aug-2026 | Source : BSE

Resignation Letter

Board Meeting Outcome for Outcome Of Board Meeting Held On 04.08.2026

04-Aug-2026 | Source : BSE

Outcome of Board Meeting held on 04.08.2026

Unaudited Financial Results Along With Limited Review Report For The Quarter Ended 30.06.2026

04-Aug-2026 | Source : BSE

Unaudited Finacial Results along with Limited Review Report for the quarter ended 30.06.2026

Corporate Actions stock-summary

stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

No Dividend history available

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available

stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
0.00%
EBIT Growth (5y)
0.00%
EBIT to Interest (avg)
0
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.02
Sales to Capital Employed (avg)
0
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.23%
ROCE (avg)
-17.18%
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
44
Price to Book Value
-1.68
EV to EBIT
-99.85
EV to EBITDA
-99.85
EV to Capital Employed
99.85
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-75.00%
ROE (Latest)
Negative BV

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2026stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Non Institution

Pledged Promoter Holdings

None

Mutual Funds

Held by 3 Schemes (0.23%)

FIIs

Held by 1 FIIs (0.01%)

Promoter with highest holding

Sandeep Kumar Reddy Tikkavarapu (21.59%)

Highest Public shareholder

Fursa Mauritius Spv 1 (23.48%)

Individual Investors Holdings

53.27%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Jun'26 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2026 is 0.00% vs 0.00% in Jun 2025",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2026 is 61.54% vs -23.81% in Jun 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'26",
        "Jun'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2.34",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.01",
          "val2": "-0.18",
          "chgp": "105.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.11",
          "val2": "0.08",
          "chgp": "37.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "-0.10",
          "val2": "-0.26",
          "chgp": "61.54%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.43%",
          "val2": "0.00%",
          "chgp": "0.43%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2025 is 0.00% vs 0.00% in Sep 2024",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": " Growth in half year ended Sep 2025 is -20.51% vs -25.81% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.31",
          "val2": "-0.26",
          "chgp": "-19.23%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.17",
          "val2": "0.13",
          "chgp": "30.77%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "-0.47",
          "val2": "-0.39",
          "chgp": "-20.51%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Standalone) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is -25.45% vs -22.22% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.43",
          "val2": "-0.35",
          "chgp": "-22.86%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.26",
          "val2": "0.21",
          "chgp": "23.81%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "-0.69",
          "val2": "-0.55",
          "chgp": "-25.45%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Standalone) - Mar'26",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2026 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2026 is -52.05% vs -7.35% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.75",
          "val2": "-0.45",
          "chgp": "-66.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.36",
          "val2": "0.28",
          "chgp": "28.57%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "-1.11",
          "val2": "-0.73",
          "chgp": "-52.05%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Standalone) - Jun'26 - YoYstock-summary

Jun'26
Jun'25
Change(%)
Net Sales
2.34
0.00
Operating Profit (PBDIT) excl Other Income
0.01
-0.18
105.56%
Interest
0.11
0.08
37.50%
Exceptional Items
0.00
0.00
Standalone Net Profit
-0.10
-0.26
61.54%
Operating Profit Margin (Excl OI)
0.43%
0.00%
0.43%
Values in Rs Cr.
Net Sales

YoY Growth in quarter ended Jun 2026 is 0.00% vs 0.00% in Jun 2025

Direction Arrows
Standalone Net Profit

YoY Growth in quarter ended Jun 2026 is 61.54% vs -23.81% in Jun 2025

Half Yearly Results Snapshot (Standalone) - Sep'25stock-summary

Sep'25
Sep'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-0.31
-0.26
-19.23%
Interest
0.17
0.13
30.77%
Exceptional Items
0.00
0.00
Standalone Net Profit
-0.47
-0.39
-20.51%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
Values in Rs Cr.
Net Sales

Growth in half year ended Sep 2025 is 0.00% vs 0.00% in Sep 2024

Direction Arrows
Standalone Net Profit

Growth in half year ended Sep 2025 is -20.51% vs -25.81% in Sep 2024

Nine Monthly Results Snapshot (Standalone) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-0.43
-0.35
-22.86%
Interest
0.26
0.21
23.81%
Exceptional Items
0.00
0.00
Standalone Net Profit
-0.69
-0.55
-25.45%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
Values in Rs Cr.
Net Sales

YoY Growth in nine months ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Direction Arrows
Standalone Net Profit

YoY Growth in nine months ended Dec 2025 is -25.45% vs -22.22% in Dec 2024

Annual Results Snapshot (Standalone) - Mar'26stock-summary

Mar'26
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-0.75
-0.45
-66.67%
Interest
0.36
0.28
28.57%
Exceptional Items
0.00
0.00
Standalone Net Profit
-1.11
-0.73
-52.05%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
Values in Rs Cr.
Net Sales

YoY Growth in year ended Mar 2026 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Standalone Net Profit

YoY Growth in year ended Mar 2026 is -52.05% vs -7.35% in Mar 2025

stock-summaryCompany CV
About Gayatri BioOrganics Ltd stock-summary
stock-summary
Gayatri BioOrganics Ltd
Micro Cap
Commodity Chemicals
Gayatri BioOrganics Limited was initially incorporated as 'Starchem Industries Limited' on December 2, 1991. Later on, the name was changed to Gayatri Starchem Limited on 24 October, 1997. On 13th February, 2008, the name was further changed to Gayatri BioOrganics Limited. It was promoted jointly by T V Sandeep Reddy and D S P Reddy and Associates.
Company Coordinates stock-summary
Company Details
6-3-1090 B-Block 3rd Floor, TSRTowersRajbhavan RdSomajigud Hyderabad Telangana : 500082
stock-summary
Tel: 91-40-66100111
stock-summary
info@gayatribioorganics.com
Registrar Details
Venture Capital & Corporate Investments Ltd , 12-10-167,, MIG- 167,, Bharat Nagar Colony, Hyderabad